Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

  |  Issue: March 2017  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Monti S, Klersy C, Gorla R, et al. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: Real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Jan 5. doi:10.1007/s10067-016-3528-y. [Epub ahead of print]
  2. Cohen S. Perspective: Comorbidities, older age may influence choice of abatacept. Healio. 2017 Jan 20.
  3. Hanlon JT, Perera S, Newman AB, et al. Potential drug–drug and drug–disease interactions in well-functioning community-dwelling older adults. J Clin Pharm Ther. 2017 Jan 22. doi: 10.1111/jcpt.12502. [Epub ahead of print]
  4. Can-Fite BioPharma Ltd. Can-Fite gears up for ACRobat, its Phase III trial of piclidenoson in rheumatoid arthritis. 2017 Feb 8.
  5. BioNap Inc. Can-Fite phase 3 RA program ready to start. 2017 Feb 8.

Related Articles